Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Ragweed Compounds Could Protect Nerve Cells From Alzheimer’s

By American Chemical Society | May 17, 2019

As spring arrives in the northern hemisphere, many people are cursing ragweed, a primary culprit in seasonal allergies. But scientists might have discovered a promising new use for some substances produced by the pesky weed. In ACS’ Journal of Natural Products, researchers have identified and characterized ragweed compounds that could help nerve cells survive in the presence of Alzheimer’s disease (AD) peptides.

Those with AD, a neurodegenerative disorder, often have impaired judgment, cognition, memory and behavior. Scientists have linked AD to the accumulation of amyloid-β (Aβ) peptides in the brain, which form plaques that kill nerve cells. Unfortunately, the five drugs currently approved for AD treatment only delay disease progression for a short time. When Won Keun Oh and colleagues screened 300 natural plant extracts for activity against AD in a preliminary study, they found a surprising candidate: Ambrosia artemisiifolia (common ragweed). This invasive weed, native to North America, has now spread to South America, Asia and much of Europe. Oh and colleagues decided to isolate and characterize the structures of ragweed compounds responsible for this neuroprotective activity.

The researchers isolated 14 compounds from whole ragweed plants that appeared to protect neurons from Aβ-induced toxicity. They determined the structures of the compounds with nuclear magnetic resonance, mass spectrometry and other analytical techniques. Seven of the chemicals, including terpenoids and spermidine conjugates, had been described previously, but the remainder were newly identified terpenoids. When the researchers added the two most active new compounds to a lab dish that contained neurons producing Aβ, about 20 percent more cells survived than without treatment.

Related Articles Read More >

Biogen
Biogen bets $1.5B on Sage Therapeutics’ neurological drugs
ISRIB
Drug seems to reverse age-related cognitive decline in mice
DNA genotyping and sequencing
How COVID-19 has affected Big Pharma and biotech
Amylyx
Amylyx Pharmaceuticals wins orphan drug designation from FDA

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards